| Ytd | -9.03% | |
| 1y | -2.08% |
| Open | 1.45 | Prev Close | 1.44 | Low | 1.38 | High | 1.46 | Mkt Cap | 89.41M |
| Vol | 522.00K | Avg Vol | 583.72K | EPS | -0.14 | P/E | N/A | Forward P/E | -0.47 |
| Beta | 1.83 | Short Ratio | 0.53 | Inst. Own | 20.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 2.05 | 200-d Avg | 2.08 | 1yr Est | 3.33 |
EQ News
New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipa
New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune re
Equillium (NASDAQ: EQ) Chief Scientific Officer Stephen Connelly outlined the company's plans to adv
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advan
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasd
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approxi
Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Modera
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweigh
Three-year renewal follows early campaign results that delivered up to 40% increases in average orde
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology in
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammator
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
Leerink Partners analyst Thomas Smith upgrades Equillium (NASDAQ:EQ) from Market Perform to Outpe
LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.06) per share which missed the analyst consen
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected appro
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology inn
DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup wit
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology i
B. Riley Securities analyst William Woods initiates coverage on Equillium (NASDAQ:EQ) with a Buy
Raymond James analyst Martin Auster initiates coverage on Equillium (NASDAQ:EQ) with a Strong Buy
Cantor Fitzgerald analyst Emma Nealon initiates coverage on Equillium (NASDAQ:EQ) with a Overweig
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.04) per share which beat the analyst consensu
Roth Capital analyst Adam Walsh initiates coverage on Equillium (NASDAQ:EQ) with a Buy rating and
